MRA Research Publications
MRA investigators have published 17 papers in high impact journals describing research that was funded wholly or in part by MRA.
Brahmer JR, Drake CD, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28:3167, 2010.
Gerami P, Pouryazdanparast P, Vemula S, Bastian BC. Molecular Analysis of a Case of Nevus of Ota. American Journal of Dermatopathology, 32:301, 2010.
Li Y, Depontieu FR, Sidney J, Salay TM, Engelhard VH, Hunt DF, Sette A, Topalian SL, Mariuzza RA. Structural basis for the presentation of tumor-associated MHC class-II restricted phosphopeptides to CD4+ T cells. Journal of Molecular Biology, 399:596, 2010.
Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE and Garraway LA. An oncogenic role for ETV1 in melanoma. Cancer Research, 70:2075, 2010.
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature, 464:427, 2010.
Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. Integrative analysis of the melanoma transcriptome. Genome Research, 20:413, 2010.
Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR. p85 associates with unphosporylated PTEN and the PTEN-associated complex. Molecular and Cellular Biology, 29:5377, 2009.
Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman R, Heine AI, Terzulli SL, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor response to ipilimumab therapy. Cancer Immunity, 10:1, 2010.
Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. MEK1 mutations confer resistance to MEK and BRAF inhibition. Proceedings of the National Academy of Sciences USA, 106:20411, 2009.
Ren G, Miao Z, Liu J, Jiang L, Limpa-Amara N, Mahmood A, Gambhir SS, Cheng Z. Melanin-targeted preclinical PET of melanoma metastasis. Journal of Nuclear Medicine, 50:1692, 2009.
Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature, 457:599, 2009. Abstract:
Jinushi M, Nakazaki Y, Carrasco DR, Draganov D, Souders N, Johnson M, Mihm MC, Dranoff G. Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and Twist signaling in the tumor microenvironment. 2008. Cancer Research, 68(21):8889–98.
Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. British Journal of Cancer, 101:813, 2009.
Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S, Dranoff G, Tahara H. Milk fat globule epidermal growth factor–8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. 2009. Journal of Experimental Medicine, 206(6):1317-1326.
Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL. Identification of tumor-associated, MHC class II restricted phosphopeptides as targets for immunotherapy. 2009. Proceedings of the National Academy of Sciences USA, 106(29):12073-12078.
Hadrup SR, Bakker AH, Shu CJ, Andersen RS, Veluw J, Hombrink P, Castermans E, Straten P, Blank C, Haanen JB, Heemskerk MH, Schumacher TN. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. 2009. Nature Methods, 6(7): 520-526.
Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Kua GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman R, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. 2008. Proceedings of the National Academy of Sciences USA, 105 (51):20410-20415.